By subscription, you consent to allow Ubigene Biosciences to store and process the information
provided above to deliver the latest news, research spotlight, and promotions. You can unsubscribe
from these communications at anytime.
Ubigene has modified over 5000 genes from more than 200 cell lines with our exclusive innovation
CRISPR-U™ technology. At the same time, we already provide customers with high quality gene-editing
tools for cell or animal research worldwide.
With 14 years of experience, Ubigene has exclusively innovated and developed 6 product lines,
fullfilling all kinds of needs from researchers. Experiment process simplified, efficiency improved,
achieving our aim of 'Make genome editing easier'!
DEPDC1 is a potential therapeutic target in lung adenocarcinoma
IF=17.4
Nano Today
Author: Liuxiang Wang , Yueguang Xue , Xinlian Wang, Yue Pan, Shilin Li , Jie Mei, Shasha Jiang , Qian Zheng, Yang Liu, Ying Liu , Jing Yuan, Yongfu Ma